Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Tilray Brands Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Tilray Brands Inc trades at $3.11 (market cap $481.79M). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 17.6× Tilray Brands Inc's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| HNGE | TLRY | |
|---|---|---|
Market Cap | $8.48B | $481.79M |
Volume | 879,799 | 4,056,443 |
Sector | Health | Health |
52-Week High | $105.14 | $16.80 |
52-Week Low | $31.17 | $3.14 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $8.10B | $635.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Tilray Brands (TLRY) trades at $3.27, down 2.68% on the day and near 52-week lows, with bearish technical signals dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings misses and negative cash flow from operations highlight ongoing profitability challenges despite analyst consensus pointing to significant upside potential.
TLRY presents a high-risk opportunity with substantial analyst price target divergence. While valuation metrics appear attractive (P/S 0.4x, P/B 0.3x), persistent losses and cash burn require careful monitoring. The stock's fate hinges on cannabis reform progress and the company's ability to achieve sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
